The Patent Finder
AP

Aventis Pharma S.A.

Filings on record here from 2001, where this site's data begins
OverviewNotableFeesChangesFamiliesPatent listSources & methods

10 patents currently held

5 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1 more record may belong here and awaits a decision; it is not counted.

The next term ends in Feb 2027. from the record

Of the 5 now held by other companies, 4 name Sanofi Mature IP as their current owner, and 1 more name another party. Each row says which.

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
9
Ending by 2030
Feb 2027
Next term end
9
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents fee due within 90 days all others Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Oct 12, 2027
    The maintenance fee for Crystalline Form of Cabazitaxel and Process for Preparing the Same (US 9,309,210) comes due Oct 12, 2027. Unpaid by Apr 12, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 2 terms have ended since Aug 17, 2026

Patents held now

Soonest term end first.

Showing 1 to 10 of 10

PatentTitleStatusExpiresConfidence
US 7,935,819Novel Cyclic Urea Derivatives, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors
In force
 · High confidence
In forceHigh confidence
US 7,674,795Novel Fluorene Derivatives, Composition Containing Said Derivatives and the Use Thereof
In force
 · High confidence
In forceHigh confidence
US 8,058,2907-Substituted Aza-Indazoles, Compositions Containing Same, Production Method and Use Thereof
In force
 · High confidence
In forceHigh confidence
US 8,008,322Substituted Pyrazolopyridines, Compositions Containing Them, Method for the Production Thereof, and Their Use
In force
 · High confidence
In forceHigh confidence
US 8,034,939Novel Isoindole Derivatives, Compositions Containing Same, Preparation Thereof and Pharmaceutical Uses Thereof in Particular as Inhibitors of Chaperone Protein HSP90 Activities
In force
 · High confidence
In forceHigh confidence
US 8,378,128Crystalline Forms of Dimethoxy Docetaxel and Methods for Preparing the Same
In force
 · High confidence
In forceHigh confidence
US 10,160,739Crystalline Forms of Dimethoxy Docetaxel and Methods for Preparing the Same
In force
 · High confidence
In forceHigh confidence
US 8,163,7681,4-Dihydropyridine-FUSED Heterocycles, Process for Preparing the Same, Use and Compositions Containing Them
In force
 · High confidence
In forceHigh confidence
US 8,481,589Novel Taxoid-Based Compositions
In force
 · High confidence
In forceHigh confidence
US 9,309,210Crystalline Form of Cabazitaxel and Process for Preparing the Same
In force
 · High confidence
In forceHigh confidence
Also on record, not counted in the 10: 5 patents in force now held by others · 215 patents ended · 151 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
17 terminal disclaimers are on file with no resolved reference. No cap is applied and none is guessed
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited